The Patent Finder

Recordati Ireland Ltd.

Also on record
Records under this name other than the patents Recordati Ireland Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Showing 1 to 10 of 10 · Back to Recordati Ireland Ltd.

PatentTitleStatus Expires Confidence
US 9,593,127HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS
Lapsed on the fee record
Ended Mar 14, 2025 · High confidence
Lapsed on the fee recordEnded Mar 14, 2025High confidence
US 9,889,121Heterocyclylalkyne Derivatives and Their Use as Modulators of MGLUR5 Receptors
Lapsed on the fee record
Ended Feb 13, 2022 · High confidence
Lapsed on the fee recordEnded Feb 13, 2022High confidence
US 8,580,962Spiroheterocyclic compounds as mGlu5 antagonists
Lapsed on the fee record
Ended Nov 12, 2021 · From the USPTO record
Lapsed on the fee recordEnded Nov 12, 2021From the USPTO record
US 6,333,044Therapeutic compositions for intranasal administration which include KETOROLAC.RTM.
Formerly held
Term ended
Term ended Dec 25, 2018 · From the USPTO record
Term endedTerm ended Dec 25, 2018From the USPTO record
US 7,683,179Lercanidipine salts
Lapsed on the fee record
Ended Mar 23, 2018 · From the USPTO record
Lapsed on the fee recordEnded Mar 23, 2018From the USPTO record
US 8,518,916Heterocyclic derivatives as M-GLU5 antagonists
Lapsed on the fee record
Ended Aug 27, 2017 · From the USPTO record
Lapsed on the fee recordEnded Aug 27, 2017From the USPTO record
US 6,852,737Crude and crystalline forms of lercanidipine hydrochloride
Lapsed on the fee record
Ended Feb 8, 2017 · From the USPTO record
Lapsed on the fee recordEnded Feb 8, 2017From the USPTO record
US 7,267,827Therapeutic compositions for intranasal administration which include KETOROLAC
Formerly held
Term ended
Term ended Sep 6, 2015 · From the USPTO record
Term endedTerm ended Sep 6, 2015From the USPTO record
US 7,476,689Therapeutic compositions for intranasal administration which include KETOROLAC
Formerly held
Term ended
Term ended Oct 11, 2012 · From the USPTO record
Term endedTerm ended Oct 11, 2012From the USPTO record
US 5,798,362Quinazolinyl-amino derivatives having .alpha.-antagonist activity
Term ended
Term ended no later than Aug 25, 2018 · Low confidence
Term endedTerm ended no later than Aug 25, 2018Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited